Holen Sie sich die Stockscreener-App
14.53
8.43%
1.13
Handel nachbörslich:
14.36
-0.17
-1.17%
Schlusskurs vom Vortag:
$13.40
Offen:
$13.49
24-Stunden-Volumen:
247.70K
Relative Volume:
1.98
Marktkapitalisierung:
$126.88M
Einnahmen:
$123.24M
Nettoeinkommen (Verlust:
$136.00K
KGV:
-726.50
EPS:
-0.02
Netto-Cashflow:
$-148.99M
1W Leistung:
+3.27%
1M Leistung:
+52.79%
6M Leistung:
-15.73%
1J Leistung:
-46.58%
1-Tages-Spanne:
$13.32
$15.41
1-Wochen-Bereich:
$11.15
$15.41
52-Wochen-Spanne:
$6.53
$29.40
Seres Therapeutics Inc Stock (MCRB) Company Profile
Firmenname
Seres Therapeutics Inc
Sektor
Branche
Telefon
617 945 9626
Adresse
200 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie MCRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
14.53 | 117.01M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-08 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-04-21 | Eingeleitet | JP Morgan | Neutral |
| 2021-07-23 | Herabstufung | Goldman | Neutral → Sell |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-03-05 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-11 | Hochstufung | Jefferies | Hold → Buy |
| 2019-04-30 | Eingeleitet | Jefferies | Hold |
| 2018-10-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-08-04 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-01 | Bestätigt | FBR & Co. | Outperform |
| 2016-08-12 | Bestätigt | FBR Capital | Outperform |
| 2016-08-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Bestätigt | H.C. Wainwright | Buy |
| 2016-07-29 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-03-30 | Eingeleitet | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | Guggenheim | Buy |
| 2016-01-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-10-22 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-07-21 | Eingeleitet | Goldman | Neutral |
| 2015-07-21 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Seres Therapeutics Inc Aktie (MCRB) Neueste Nachrichten
What is the dividend policy of Seres Therapeutics Inc. stockExceptional market performance - jammulinksnews.com
What institutional investors are buying Seres Therapeutics Inc. stockRealize exceptional returns through smart trading - jammulinksnews.com
How does Seres Therapeutics Inc. compare to its industry peersUnmatched market gains - jammulinksnews.com
When is Seres Therapeutics Inc. stock expected to show significant growthBreakout profit opportunities - jammulinksnews.com
How many analysts rate Seres Therapeutics Inc. as a “Buy”Invest smarter and grow your wealth faster - jammulinksnews.com
Should I hold or sell Seres Therapeutics Inc. stock in 2025High-octane investment opportunities await - jammulinksnews.com
Is Seres Therapeutics Inc. a growth stock or a value stockGain insights from top financial experts - jammulinksnews.com
What are Seres Therapeutics Inc. company’s key revenue driversGet expert alerts on market-moving stocks - jammulinksnews.com
Seres Therapeutics announces leadership transition - MSN
Why Seres Therapeutics Inc. stock attracts strong analyst attentionMarket Beating Strategy - Metal.it
Is Seres Therapeutics Inc. a good long term investmentRapid profit acceleration - PrintWeekIndia
Will Seres Therapeutics Inc. stock benefit from AI tech trendsHigh-yield capital appreciation - jammulinksnews.com
What risks could impact Seres Therapeutics Inc. stock performancePhenomenal capital appreciation - jammulinksnews.com
What analysts say about Seres Therapeutics Inc. stockFree Stock Market Beginners Guide - PrintWeekIndia
Why Seres Therapeutics Inc. stock is on top investor watchlistsHigh-yield capital appreciation - jammulinksnews.com
What institutions are buying Seres Therapeutics Inc. stock nowBreakneck growth rates - jammulinksnews.com
What drives Seres Therapeutics Inc. stock priceUnprecedented growth rates - Autocar Professional
Seres Therapeutics Inc. Stock Analysis and ForecastFree Consultation - Autocar Professional
Seres Therapeutics Soars 10.98% on Leadership Transition - AInvest
Seres Therapeutics stock jumps after naming co-CEOs By Investing.com - Investing.com Canada
Seres Therapeutics (MCRB) Announces Transition in Executive Lead - GuruFocus
Seres Therapeutics Announces Leadership Transition - The Manila Times
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 - The Manila Times
Seres Therapeutics to Host Conference Call on August 6, 2025, to Discuss Q2 Financial Results and Business Updates - Quiver Quantitative
Seres Therapeutics Appoints Dual CEOs, Explores Deals as Breakthrough Drug Shows Promising Results - Stock Titan
Seres Therapeutics, Inc.'s (NASDAQ:MCRB) top owners are individual investors with 51% stake, while 23% is held by institutions - Yahoo Finance
individual investors who own 52% along with institutions invested in Seres Therapeutics, Inc. (NASDAQ:MCRB) saw increase in their holdings value last week - simplywall.st
what makes seres therapeutics inc. stock price move sharplyChart Breakout Alert - Newser
How high can Seres Therapeutics Inc. stock price go in 2025Protected Capital Trading Plan - Newser
What makes Seres Therapeutics Inc. stock price move sharplyFree Trading Group - Newser
How Seres Therapeutics Inc. stock performs during market volatilityWatchlist Winner Update - Newser
Finanzdaten der Seres Therapeutics Inc-Aktie (MCRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):